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Most human genes undergo alternative splicing, and many abnormal splicing processes 
are associated with human diseases. However, the molecular relationship between 
alternative splicing and tumorigenesis is not well understood. Here, we identified novel 
Krüppel-like factor 4 (KLF4) splicing variants produced by exon skipping in human 
cancer cell lines as well as colon tumor tissues. To elucidate the mechanism involved in 
KLF4 alternative splicing, we developed KLF4 minigene system and found that RNA 
binding motif protein 5 (RBM5) plays an important role in KLF4 splicing, as assessed by 
gain and loss of functional studies. Several anti-tumorigenic compounds were also tested 
for KLF4 splicing. Interestingly, sulindac sulfide restored wild type KLF4 (KLF4L) 
expression and this is mediated by dephosphorylation of RBM5. Another splicing variant, 
small KLF4 (KLF4S), localizes in the cytoplasm and nucleus, and antagonizes 
transcriptional activity of wild type KLF4. Our data suggest that RBM5 plays a pivotal 
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1.1. Colorectal cancer  
Colorectal cancer is the third most common cancer and leading cause of cancer death in 
the United States; approximately 5-7% of individuals developing colorectal cancer. 
Based on the National Cancer Institute Surveillance Epidemiology and End Results 
(SEER) Stat Fact Sheet, it is estimated that 142,570 people (72,090 men and 70,480 
women) will be diagnosed with and 51,370 people will die of colorectal cancer in 2010. 
The risk of colorectal cancer starts to increase before age 50 and significantly boosts in 
the 60s and 70s (Chan and Giovannucci 2010). Around 70% of colorectal cancers are 
found in the first six feet of the colon and the other 30% occur in the last 10 inches of the 
rectum (Figure 1-1). It is evident that further studies with molecular-based approach are 
required to reduce incidence and risk of colorectal cancer. 
 
Figure 1-1. Colon cancer and polyp. The human colon has four sections, including 
ascending, transverse, descending, and sigmoid colon. Benign polyps develop when 
DNA damage occurs in the inner lining of the colon cell (Right). Over the years, 
polyps in the colon are able to become colon cancer (Left).  Illustration from 
Medicine Net. Inc. 
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1.2. Hereditary colorectal cancer 
There are many risk factors for colorectal cancer, such as genetic background, age, diet, 
and carcinogen exposure. About 67-95% of colorectal cancers are sporadic and the other 
5-33% are hereditary (Burt and Neklason 2005, Grady 2003) (Figure 1-2).  
In case of genetic factor, hereditary colorectal cancer can be classified into four groups 
depending on types and patterns of adenomas (Abdel-Rahman and Peltomaki 2004). The 
first group is more than thousands of adenomas polyps are able to become malignant 
including familial adenomatous polyposis (FAP) and Turcot’s syndrome. The second 
group is less than 1000 adenomatous polyps within the colon such as MYH-associated 
polyposis. The third group is a few adenomas with the capacity to turn malignant 
including hereditary nonpolyposis colorectal cancer syndrome (HNPCC), also known as 
Lynch syndrome. Final group is syndromes with hamartomatous polyps which contain a 
mixture of normal and inflammatory polyps, such as Peutz-Jeghers syndrome, familial 
juvenile polyposis and Cowden syndrome (Schreibman et al 2005). However, FAP and 
HNPCC is the most common hereditary colorectal cancer (Figure 1-2).  
 
Figure 1-2. Colon cancer and inheritance. Around 33% cases of colorectal cancer is 
hereditary and rest of cases are sporadic (Figure from Burt and Neklason 2005).  
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FAP is an autosomal dominant syndrome in which over a thousand polyps develop in the 
patient’s colon. FAP is caused by mutation of adenomatous polyposis (APC) gene, which 
is a tumor-suppressor gene (Burt and Neklason 2005). Mutation of APC causes 
constitutive activation of Wnt-signaling pathway, resulting in uncontrolled cell growth 
(Goss and Groden 2000).  Approximately 95% of APC mutations produce truncated APC 
protein by frameshift or nonsense mutation (Sieber et al 2000). Because these truncations 
cause loss of the domains required for binding to β-catenin and to microtubules. The 
interaction of APC with β-catenin and microtubules is essential for its tumor suppressor 
activity (Aoki and Taketo 2007). 
HNPCC is also an autosomal dominant syndrome which has colon cancer as well as 
endometrium, ovary, stomach, small intestine, gastric, urinary tract, renal cell, 
gallbladder, skin, and brain (Lynch et al 1993). HNPCC is associated with mutations of 
mutation mismatch repair (MMR) gene including MutL homolog 1 (MLH1), MutS 
homolog 2 (MSH2), and MutS homolog 6 (MSH6) (Burt and Neklason 2005). MMR 
system, which is DNA mismatch repair system, consists of a complex of proteins that 
recognize and repair the mismatched base-pairs during DNA replication. In addition, 
Some HNPCC patients have microsatellite instability (MSI), which is mutation by defect 
of MMR system in repeated DNA sequence within a chromosome. MSI cancer cells 
show 100 times more mutation rate than microsatellite stable cancer cells (Lynch 1999). 
Therefore, mutation in the MMR gene showed severe phenotypes by accumulations of 
mismatch repairs. Although there has been many studies involving hereditary colorectal 
cancer, sporadic colorectal cancer accounts for around 70% of colorectal cancers. 
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Therefore, the detailed molecular mechanism of sporadic colorectal cancer needs to be 
investigated. 
 
1.3. Genetic markers in colorectal cancer 
Colon cancer progression involves the accumulation of sequential events that either 
activate oncogenes or inhibit the action of tumor suppressor genes, resulting in the 
transformation of normal colonic epithelial cells into adenocarcinoma which takes 
between 10 to 15 years (Figure 1-3). The most commonly affected genes in this process 
including APC, KRAS, BRAF, SMAD4, BAX, CDC4, and p53 (Grady 2005, Walther et 
al 2009).  
Many reports have suggested that mutations in APC gene are responsible for colorectal 
cancer. Generally, APC plays an important role in the regulation of cytoplasmic β-catenin 
by formation of multi-protein complex with Casein Kinase 1α (CK1α), Axin, and 
glycogen synthase kinase-3β (GSK-3β). Once β-catenin is bound to this complex, it is 
phosphorylated by CK1α and GSK-3β, which promotes its ubiquitin-mediated 
proteasomal degradation (Aoki and Taketo 2007, Fearon 1995). 
On the other hand, Wnt signaling pathway involves the stabilization and nuclear 
translocation of β-catenin. Once Wnt ligand binds and activates their membrane receptor, 
Frizzled, cytoplasmic Dishevelled (Dvl) induces phosphorylation of Axin and 
degradation of down steam targets. As a result of the degradation, β-catenin 
phosphorylation is prevented and is free to translocate into the cell nucleus. Nuclear β-
catenin is a co-activator of the T-Cell Factor (TCF)/Lymphoid Enhancer Factor (LEF) 
family of transcription factors that induce the transcription of several target genes that 
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control tumorigenesis including cyclin D1, CD44, PPARδ, and c-MYC (He et al 1998, 






Figure 1-3. Chromosomal instability model of colorectal cancer. The initial step in 
tumorigenesis is associated with loss of adenomatous polyposis (APC) to form early 
adenoma. Mutations in KRAS, which is a small GTPase, are allowed to form 
intermediate adenoma. Next, late adenoma acquires loss of SMAD4, which is 
downstream of transforming growth factor-β (TGF-β) in chromosome 18q. Finally, 
mutations in p53 result in carcinoma. In addition, microsatellite instability 
including Wnt signaling pathway, BRAF, CDC4, and BAX is linked to each step of 





It has been reported that mutation of RAS in human cancer is common and around 20% 
of all human cancer has a mutation in one of the RAS genes. RAS is a protein that plays 
an important role in controlling the activity of several signaling pathways that are 
responsible for the regulation of cell proliferation. The presence of mutant RAS is 
responsible for the deregulation of cellular processes such as programmed cell death, 
angiogenesis, and tumor invasion. Three different members of the RAS family are found 
to be mutated in human cancer, including H-RAS, K-RAS and N-RAS (Downward 2003). 
Especially K-RAS is important in colorectal tumorigenesis. The target of RAS is RAF, a 
serine/threonine kinase. Once phosphorylated, RAF activates mitogen-activated protein 
kinase (MAPK) cascades, including MEK1/2 and Erk1/2. The activation of Erk induces 
its translocation to the cell nucleus, where it promotes the formation of the AP-1 
transcription factor (FOS/JUN) that regulates the expression of proteins such as cyclin D1. 
Several reports have established that the particular effects of the RAS signaling pathway 
are strongly influenced by the cellular context. For example, the presence of activated 
RAS in immortalized cells promotes tumorigenesis, whereas in primary cells, activated 
RAS can induce cell cycle arrest (Mulder 2000).  
Many studies show that TGF-β has the ability to regulate both cell proliferation and 
apoptosis at different stages of colon cancer development. SMAD is downstream of this 
pathway and also involved in transition stage from intermediate adenoma to late adenoma 
in coloreactal tumorigenesis (Derynck and Zhang 2003, Fearon and Vogelstein 1990).  
Especially, SMAD4 is an important tumor suppressor gene is located in chromosome 
18q21, a region with frequent genetic losses in colorectal cancer (Alazzouzi et al 2005). 
The receptor-phosphorylated SMAD2 and SMAD3 demonstrate high affinity for SMAD4 
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binding. Once the complex SMAD2/3 and SMAD4 is formed, the complex translocates 
into the nucleus where it regulates the transcription of genes regulated by TGF-β.  
 
1.4 KLF4 expression in cancer 
So far, at least 25 members of Krüppel-like factor (KLF) family have been reported in 
human including SP1-like and KLF-like factors (Dang et al 2000b, Kaczynski et al 2003, 
Suske et al 2005, Turner and Crossley 1999). Particularly, KLF4 is strongly associated 
with tumorigenesis and regulation of proliferation of GI tract epithelium (Wei et al 2006). 
KLF4 is a member of the C2H2-type zinc finger protein family, also known as gut-
enriched KLF (GKLF) or epithelial zinc finger (EZF) (Garrett-Sinha et al 1996). KLF4 
binds to GC-rich elements, which is a conserved DNA binding sequence CACCC in the 
promoter region (Sogawa et al 1993). KLF4 acts as a transcription regulator to diverse 
target genes involved in cell differentiation, proliferation, and apoptosis (Katz et al 2002, 
Rowland and Peeper 2006, Wei et al 2006, Yoon et al 2003) (Table 1).  
KLF4 protein is highly expressed in epithelial tissues, including the skin, lung, and 
intestine. In addition, KLF4 is detected in the differentiated terminal epithelial cells in the 
villus border of the small intestine and the upper crypt region of the large intestine (Ton-
That et al 1997). Significant reduction of KLF4 mRNA levels was detected in colorectal 
adenoma and adenocarcinoma, compared with normal tissues, suggesting relevance of 
KLF4 in colorectal tumorigenesis (Dang et al 2000a, Wei et al 2005).  
In vivo study using KLF4 knockout mice showed that KLF4 is essential for the barrier 
function of skin and for terminal differentiation of goblet cells in the colon of newborn 
mice (Katz et al 2002, Segre et al 1999). Moreover, it has been shown that KLF4 
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interacts with β-catenin and inhibits β-catenin signaling, suggesting that cross talk 
between KLF4 and β-catenin plays an important role in colorectal tumorigenesis (Zhang 
et al 2006).  
It has been shown that KLF4 has dual functions such as tumor suppressor and oncogenic 
activity in tumorigenesis (Rowland and Peeper 2006, Wei et al 2006). In tumor 
suppressor aspect of KLF4, deletion mutation and methylation on the KLF4 gene locus 
were found in coloreactal and gastric cancers (Wei et al 2005, Zhao et al 2004). In 
addition, gastric tissue specific KLF4 knockout mice showed development of hyperplasia 
and polyps in stomach compared with wild type (Katz et al 2005). Investigation of human 
gastric cancer patients revealed that loss of KLF4 takes places at early stages in the 
progression of cancer (Wei et al 2005). 
In contrast, ectopic overexpression of KLF4 in basal keratinocytes using inducible 
transgenic mice showed that squamous hyperplasia and dysplasia, indicating the 
oncogenic effect of KLF4 (Foster et al 2005), and overexpression of KLF4 was found 
around 70% of primary human breast cancers (Foster et al 2000). KLF4 has been shown 
as a downstream of p53 such that KLF4 is required for p53-mediated induction of cyclin-
dependent kinase inhibitor 1A (CDKN1A or p21CIP/WAF) in response to DNA damage 
resulting cell cycle arrest (Zhang et al 2000). Even though many clinical evidences and 
genetic and cell biology studies have shown a strong association between KLF4 and 
tumorigenesis, the regulation of KLF4 itself including transcription, post-transcription, 





Table 1. KLF4 regulated genes (modified from Wei et al., 2006).  











Laminin α 3A 
Laminin γ-1 chain 
Intestinal alkaline phosphatase 














Cyclin-dependent kinase inhibitor 
Cell differentiation 







Cell cycle, DNA damage 


























1.5 NSAIDs in colorectal cancer  
Nonsteroidal ant-inflammatory drugs (NSAIDs), including aspirin, indomethacin, 
piroxicam, ibuprofen, and sulindac, are used to treat pain, fever, and inflammation 
(Ulrich et al 2006). NSAIDs inhibit the activity of cycloxygenase-2 (COX-2) enzymes 
that plays a key role in the prostaglandin biosynthesis (Vane 1971). Arachidonic acid 
(AA), the common precursor of eicosanoids, is stored at the membrane 
glycerophospholipids and released by the hydrolytic action of phospholipase A2 (PLA2) 
enzymes. Next, AA is metabolized to the unstable intermediate prostanoid, PGH2, by the 
action of COX enzymes (COX-1 and COX-2). It is generally considered that COX-1 is 
constitutively expressed in a variety of cells and plays a housekeeping role. However, 
COX-2 is a stimulus-inducible enzyme that is associated with inflammation, pain, fever 
and cancer. In table 2, COX-1 or COX-2 specific NSAIDs are listed (Ulrich et al 2006). 
In addition to their anti-inflammatory activity, NSAIDs are effective chemopreventive 
agents against colorectal cancer (Chan et al 2005, Thun et al 1991).  However, long term 
treatment of aspirin and other NSAIDs can result in gastrointestinal ulceration and 
bleeding. This gastric problem is due to chronic inhibition of prostaglandin production 
via COX-1 inhibition in the gastric mucosa (Williams et al 1999). COX-2 selective 
inhibitors do not exhibit these side effects (Masferrer et al 1994); however, recent studies 
suggest that COX-2 selective inhibitors exhibit cardiovascular toxicity (McGettigan and 
Henry 2006, Solomon et al 2005). 
It has been shown that sulindac treatment to FAP patients showed complete regression of 
colorectal adenomatous polyps in some cases, and partial regression (Luk 1996). 
Sulindac is a pro-drug metabolized by the liver and the colonic bacteria by irreversible 
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oxidation to sulindac sulfone and reversible reduction to sulindac sulfide (Figure 1-4). 
The animal studies with sulindac derivatives showed approximately twice as potent as 
sulindac in suppressing tissue inflammation (Hare et al 1977, Shen and Winter 1977). In 
addition, sulindac sulfide is at least 5,000 fold more potent than sulindac sulfone at 
inhibiting prostaglandin synthesis (Piazza et al 1997). However, molecular mechanism of 
sulindac sulfide to prevent colorectal tumorigenesis has not been elucidated in details. 
 
 
Figure 1-4. Sulindac sulfide is a metabolite from sulindac by colonic bacteria 










Table 2. NSAIDs and COX inhibition (modified from Ulrich et al., 2006).  









































COX1 and COX2 
COX1 selective 
COX2 selective 
COX1 and COX2 
COX1 and COX2 
COX1 and COX2 
COX1 and COX2 
COX1 selective 
COX1 and COX2 
COX1 selective 
COX2 selective 
COX1 and COX2 
COX1 and COX2 
COX2 selective 
COX1 and COX2 




Rheumatic diseases, inflammation, pain 
Rheumatic diseases 
Rheumatic diseases, pain 
Rheumatic diseases, inflammation 
Rheumatic diseases. Inflammation 
Rheumatic diseases 
Rheumatic diseases, pain, fever 
Rheumatic diseases, pain 
Rheumatic and heart diseases, pain, inflammation 
Rheumatic diseases, pain 




Rheumatic diseases, pain 
Rheumatic diseases 
Rheumatic diseases, pain 
Rheumatic diseases, pain 







1.6 mRNA splicing 
Most of eukaryote genes contain multiple exons and introns. In order to eliminate non-
coding regions of precursor mRNAs (pre-mRNAs), conserved RNA sequences are 
marked in boundaries between exons and introns. 5’ splice site (donor) and 3’ splice site 
(acceptor) refer to as the GU-AG role. The branch point sequence (BPS) is necessary to 
mRNA splicing process as well (Figure 1-5). The splicing reaction is mediated by the 
spliceosome, and consists of five small nuclear RNA and core protein with hundreds of 
associated proteins (Black 2003). Most of splicing processes obey the GU-AG rule; 
however, some minor case reported the AU-AC rule in exon-intron recognition sites 
(Tarn and Steitz 1996). Depending upon nucleotides variation from the consensus 
sequences on the 5’ or 3’ splice site, the binding affinity of the spliceosome could be 
changed.  
 
Figure 1-5. Consensus sequences for the mRNA splicing. The 5’ splice site (donor) 
begins with a GU dinucleotide and a 3’ splice site (acceptor) ends with AG 
dinucleotide, indicated by red letters. The branch point sequence (branch site) is 
located within the middle of intron. The letter “y” indicates pyrimidine and n is any 
nucleotide (modified from Srebrow and Kornblihtt 2006).   
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1.7 Biochemical reaction of mRNA splicing 
There is two-step biochemical reaction in mRNA splicing via spliceosome and self-
splicing transesterification (Figure 1-6).  Initial biochemical step is the 2’-hydroxyl group 
of the branch point adenosine within intron starts nucleophilic attack at the 5’ splice site 
and then, intron makes a lariat intermediate form. In the second biochemical reaction, 3’-
hydroxyl group on the cleaved 5’ splice site attacks to the phosphate at the 3’ splice site 
and then, the two exons are ligated to each other and the intron lariat are released (Black 
2003, Fedor 2008).     
 
Figure 1-6. Biochemical reaction of mRNA splicing. The first step produces a intron 
lariat by nucleophilic attack from 2’-hydroxyl adenosine to the 5’ splice site (donor). 
The second step produces a free intron lariat and joined two exons by the 
nucleophilic attack from donor to acceptor (3’ splice site). Figure is modified from 
Fedor 2008.    
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1.8 Dynamic assembly of the spliceosome 
The spliceosome is a major protein complex for the pre-mRNA splicing reaction which is 
consists of five uridine-rich small ribonucleoprotein (snRNP) complexes and over 200 
accessory proteins (Black 2003, Jurica and Moore 2003). U1, U2, U4, U5, and U6 snRNP 
interact with the conserved exon-intron boundaries to catalyze intron excision and exon 
ligation (House and Lynch 2008).  
A series of spliceosome components dynamically assemble to make up several 
intermediate complexes including the E, A, B, and C complex. For the first step, the U1 
snRNP binds to the 5’ splice site and the U2 auxiliary factor heterodimer (U2AF65/35) 
binds to the polypyrimidine tract and the 3’ splice site. The U1 and U2AF bound at the 
end of intron becomes the early (E) complex or commitment complex by ATP-
independent formation (Reed 1996). The E complex recruits the U2 snRNP, which binds 
to the branch point, to form the A complex. Additional binding of tri-snRNP including 
U4, U5, and U6 becomes the B complex by SR proteins which facilitate the formation of 
the B complex in an ATP-dependent manner (Roscigno and Garcia-Blanco 1995). Finally, 
the catalytic (C) complex is formed by the extensive rearrangement of snRNPs. For 
example, the U1 snRNP is replaced with the U6 snRNP to interact with the 5’ splice site 
and the U1 and U4 snRNP is released from the spliceosome complex (Figure 1-7). The C 
complex catalyzes the two step biochemical reaction of mRNA splicing (Figure 1-6) as a 
result; exons are joined and exported to the cytoplasm for the next translation. The 
spliced lariat introns are degraded by several enzymes and many spliceosome 




Figure 1-7. Dynamic assembly of spliceosome. For the E complex the U1 snRNP 
binds to the 5’ splice site and U2AF binds to the polypyrimidine tract and 3’ splice 
site. Next, the U2 snRNP binds to the branch point to form the A complex. 
Subsequently, the U4, U5, and U6 snRNP is recruited to the spliceosome machinery 
for the B complex. Finally, dynamic rearrangement takes place in the C complex; 
U6 snRNP replaces U1 snRNP at the 5’ splice site. The U1 and U4 snRNP is released 
from the C complex (modified from House and Lynch 2008).    
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1.9 Alternative splicing patterns 
Alternative splicing is a major post-transcription regulation mechanism to generate 
multiple gene products from single primary transcript in higher eukaryotes (Black 2003). 
In 1977, the first alternative splicing was reported that showed adenoviruses produce two 
different mRNA from the same parental gene (Berget et al 1977, Chow et al 1977a, 
Chow et al 1977b).  More than 70 % of human genes undergo the alternative splicing 
(Lander et al 2001, Matlin et al 2005). In addition, the exon-exon junction microarray 
revealed that at least 74% of multi-exon genes undergo alternative splicing (Johnson et al 
2003). Therefore, alternative splicing is the primary source of the protein diversity in 
higher eukaryotes including human.  
There are six different modes of alternative splicing (Figure1-8). The constitutive splicing 
pattern is the most common splicing type which contains all exons and removes all 
introns. Second common type of alternative splicing is a cassette exon or exon skipping 
which include or exclude an exon. The different choice of 5’ or 3’ splice site can be 
altered the length of exons in the alternative 5’ and alternative 3’ splice sites. The intron 
retention is the splicing failure to remove an intron. Finally, mutually exclusive type is 
the multiple cassette exons which are spliced by the different exon skipping in several 
choices of exons (Black 2003, Srebrow and Kornblihtt 2006). Such a complex patterns of 
alternative splicing produces numerous splicing variants including insertion or deletion of 
exons, frame shift, and premature termination codon (Sorek et al 2004). The choice of 
exons in alternative spicing is regulated by interaction between cis-acting elements and 





Figure 1-8. Different patterns of alternative splicing. Constitutive splicing produces 
mRNA including all exons and excluding all intron. Exon skipping or cassette exon 
is the common splicing pattern which includes or excludes exon. Alternative 5’ or 3’ 
splice sites patterns utilizes a different splice site instead of a normal splice site. 
Intron retention is a failure of intron that usually produces a frame shift or a 
premature stop codon.  Mutually exclusive is a series of exon skipping by the 




1.10 Cis-acting elements in the alternative splicing 
Regulation of alternative splicing is similar to the transcription regulation and involves a 
cis-acting element (enhancer and silencer sequence) and trans-acting factor (repressor and 
activator protein factor). Splicing regulatory elements is named by its physical location 
such as exonic splicing enhancer (ESE), intronic splicing enhancer (ISE), exonic splicing 
silencer (ESS), and intronic splicing silencer (ISS) (Figure 1-9). These elements interact 
with trans-acting factors to activate or suppress the neighboring splicing sites (Black 
2003, Matlin et al 2005).  In case of splicing enhancer, purine rich enhancer and A/C-rich 
enhancer (GAR repeat) have been identified (Coulter et al 1997). In terms of ESE and 
ISE’s function, splicing enhancer support weak alternative splice sites and assist 
spliceosome and trans-acting factors. Compared to splicing enhancer, splicing silencer is 
not well understood but ESS and ISS probably recruits splicing repressor protein to 
suppress spliceosome assembly (Srebrow and Kornblihtt 2006).   
 
Figure 1-9. Cis-acting elements in the alternative splicing.  Exonic splicing enhancer 
(ESE) and intronic splicing enhancer (ISE) activates spliceosome assembly, 
indicated by red arrows. Exonic splicing silencer (ESS) and intronic splicing silencer 
(ISS) suppresses spliceosome, represented by blue lines (modified from Srebrow and 
Kornblihtt 2006).   
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1.11 Trans-acting factors in the alternative splicing 
There are 4 classes of trans-acting factors that regulate the alternative splicing. The 
primary factors are U1, U2, U4, U5, and U6 snRNPs which are spliceosomal components, 
interacting with 5’ splice site, 3’ splice site, polypyrimidine tract, and a branch point 
(Figure 1-7).  
The second group of factors is a serine/arginine-rich protein (SR protein) family, 
typically binding to the ESE (Figure 1-10). SR proteins are essential pre-mRNA splicing 
factors containing highly conserved the RNA-recognition motif (RRM motif) in N-
terminal and arginine/serine domain (RS domain) in C-terminal (Graveley 2000). The 
RRM motif plays a role in RNA binding and protein-protein interactions with U1snRNP 
and U2AF, suggesting that SR protein regulates splice site selection (Boukis et al 2004, 
Wu and Maniatis 1993).  
The third group is heterogeneous nuclear ribonucleoprotein (hnRNPs). The hnRNPs are 
the most abundant proteins in the nucleus. hnRNP have diverse functions including  
assisting trafficking of mRNA, associating with other splicing factors, mRNA stability, 
and polyadenylation of mRNA (Krecic and Swanson 1999). hnRNP is contains RRM 
motif for binding to mRNA and glycine-rich domain for protein-protein interaction 
(Gorlach et al 1993, Martinez-Contreras et al 2007). In case of hnRNP A1 act as a 
negative regulator which inhibit U1 snRNP in alternative splicing (Figure 1-10) (Eperon 
et al 2000). 
Final group of trans-acting factor for alternative splicing is the RNA binding motif 
(RBM) family and the CUGBP and ETR-like factors (CELF) family of protein, which 
contains RNA binding domain to activate or suppress numerous target mRNA (Han and 
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Cooper 2005).  Other factors including SR protein kinases, phosphatases, and methylases 





Figure 1-10. Trans-acting elements in the alternative splicing. The basic function of 
SR proteins binds to the exonic splicing enhancer (ESE) and promotes exon 
definition including recruitment of U2AF and U1 by protein-protein interaction 
(Left panel).  hnRNPs bind to the exonic splicing silencer (ESS), and then inhibit 
exon definition by blocking the interaction between U2AF and the 3’ splice site 
(Right panel). In addition, hnRNPs directly compete with SR protein to repress the 





1.12 alternative splicing in cancer 
A number of studies provide the importance of an alternative splicing in human diseases. 
Mutation of splicing regulatory elements on an exon or intron affects the splicing event in 
cancer (Grosso et al 2008, Venables et al 2009, Wang and Cooper 2007).  
For examples, two point mutations in exon 7 (V211 G>A) and intron 13 (A>T) of the 
BRCA2 gene splicing sites produced a truncated protein in its C-terminal region 
(Pensabene et al 2009). A splice site mutation of c-Met gene exon14 produces the 
juxtamembrane domain deletion in gastric cancer cell line Hs746T (Asaoka et al 2010). 
Mutations in cis-acting elements, such as ESE and ESS, can also disturb alternative 
splicing. For example, a point mutation of the APC tumor suppressor gene in an ESE site 
(the exon 14 1918C>G) perturbed the binding sites of SRp55, hnRNP A1 or ASF/SF2 
splicing factor. As a result, exon 14 of APC was completely skipped, leading to a frame 
shift and a premature termination codon (Goncalves et al 2009).  
Furthermore, mutations can generate new splicing regulatory elements. For example, a 
point mutation in intron 1 of the KLF6 gene generates a new binding site for the SR 
protein SRp40 (Narla et al 2005). KLF6 acts as a tumor suppressor gene and is 
somatically inactivated in prostate cancer (Narla et al 2001). The new SRp40 binding site 
produces KLF6 splicing variants which antagonize the biological functions of wild type 
KLF6.  
There are several examples of alternative splicing isoforms affect to human cancer 
including  p53, fibronectin, fibroblast growth factor (FGF) receptor, vascular endothelial 
growth factor (VEGF) receptor, CD44, and murine double minute (MDM) 2 (Hofstetter 
et al 2010, Rennel et al 2009, Srebrow and Kornblihtt 2006). Furthermore, some of the 
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alternatively spliced isoforms can accumulate in tumors and are sufficient to promote cell 
transformation and metastasis formation in cell culture (Klingbeil et al 2009, Singh et al 
2004).  
Alteration of SR factors and hnRNP proteins frequently occur in tumors and are 
accompanied by alterations in the relative abundance of alternative splicing products, a 
typical signature of cancer cells (David et al 2010, Ghigna et al 2008). Cancer cell lines 
are frequently characterized by a high level of alternative splicing events that are not 
conserved between human and mouse and are not found in physiological tissues (Kan et 
al 2005). 
 The alternative splicing of CD44, a trans-membrane glycoprotein involved in cell to cell 
and cell to matrix interactions, is a good example of how alternative splicing in cancer 
can be modulated by trans-acting factors (Naor et al 2002). The production of different 
CD44 isoforms correlates with changes in the abundance of SR proteins (Huang et al 
2007). Several CD44 isoforms have been identified diverse inclusions in proximal extra-
cellular domain of CD44 exons (v1-v10). Wild type CD44 has no alternative exons and 
predominantly expressed in normal tissues. However, CD44 isoforms, containing variant 
exons v5, v6 and v7, are over-expressed in various tumors and have been implicated in 
tumor cell invasion and metastasis (Afify et al 2008, Naor et al 2002).  
 The functional importance of trans-acting factors in cancer cells reported that splicing 
factor SF2/ASF acts as a proto-oncogene and several target genes of SF2/ASF are 
essential for the oncogenic activity of  S6K1, which is a novel oncogenic isoform of the 
mTOR substrate (Karni et al 2007). In addition, up- or down-regulation of RNA binding 
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proteins in cancer is associated with alternative splicing of oncogenes or tumor-
suppressor genes (Grosso et al 2008).  
 
1.13 RBM5 expression in cancer 
RNA binding proteins are involved in diverse RNA metabolism including RNA splicing, 
transport, translation, and stability. So far, 15 different RNA binding motif (RBM) 
proteins have been identified which contains one to four copies RBM or RNA 
recognition motif (RRM), serine/arginine-rich domain or arginine/glycine-rich domain 
(Sutherland et al 2005). RBM family proteins are involved in alternative splicing, 
apoptosis, and cancer. For example, RBM3 is down-regulated in polyglutamine tract-
induced apoptosis (Kita et al 2002) and RBM4 is involved in the splice site selection (Lai 
et al 2003). RBM7 may play a role in cell and tissue specific RNA processing (Guo et al 
2003). In addition, RBM8 is involved in spliced mRNA transport and the process of 
nonsense-mediated decay (NMD) of mRNA containing premature stop codon (Kataoka et 
al 2000, Maquat and Carmichael 2001). Although biological functions of many RBM 
proteins are still unknown, the biological function of RBM5 is relatively well studied. 
RBM5, also known as LUCA-15 or H37, is an RNA binding protein and deletion of this 
gene is found in human lung cancer (Oh et al 2002). Recently, it was found that RBM5 
regulates alternative splicing between exon-8 and -10 of caspase 2, leading to production 
of more pro-apoptotic splicing forms (Fushimi et al 2008). Moreover, alternative splicing 
of Fas pre-mRNA produces a membrane-bound receptor that promotes apoptosis and a 
soluble isoform that prevents apoptosis; Fas splicing is also regulated by RBM5, which is 
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a partner of U2AF, an important splicing factor for early splice-site recognition (Bonnal 
et al 2008, Kotlajich and Hertel 2008). In contrast, it has been reported that expression of 
RBM5 is increased in breast and ovarian cancers, correlated with HER-2/neu proto-
oncogene (Rintala-Maki et al 2007). Thus, the exact biological activity of RBM5 in 
tumorigenesis needs to be elucidated, and investigation of the alternative splicing 
















Figure 1-11. Regulation of RBM5-mediated alternative splicing. U1 snRNP and 
U2AF recognize both 5’and 3’ splice sites. Consequently, SR protein stabilizes cross-
exon interactions, resulting in constitutive alternative splicing (Left).  In the 
presence of RBM5, the interaction between SR protein and spliceosomal 
components is masked, thus promoting exon skipping by allowing cross-intron 





As discussed in chapter 1, alternative splicing may be a major contributor to 
tumorigenesis. The objective of this study was to identify the mechanism of KLF4 
alternative splicing in colorectal cancer. Based on preliminary data, we hypothesized that 
alternative splicing of KLF4 is regulated by RBM5 in colorectal cancer. Detailed 
approaches are described in chapter 3. Briefly, we identified novel alternative splicing 
variants of KLF4 in several human cancer cell lines. Sequence analysis revealed that the 
smallest KLF4 splicing variant is produced by exon skipping. In addition, we developed 
the KLF4 minigene system to investigate the exon skipping mechanism of KLF4 and 
found that regulation of alternative splicing of KLF4 is mediated by RBM5. Furthermore, 
sulindac sulfide (SS) treatment altered KLF4 alternative splicing by the 
dephosphorylation of RBM5 in colorectal cancer cells, providing a novel mechanism of 
sulindac sulfide effect in anti-cancer activity. Overall, our studies offer a novel 























2.1 Cell lines  
Human colorectal cancer cell lines (HCT-116, SW480, HT-29 and LoVo) and other cell 
lines were purchased from American Type Culture Collection (Manassas, VA). SqCC/Y1, 
which is head and neck cancer cell line, was obtained from Dr. Dong M. Shin (Emory 
University, Atlanta, GA). HCT-116 and HT-29 were maintained in McCOY’s 5A media. 
LoVo, A549 (lung cancer cell), PC-3 (prostate cancer cell) was incubated in Ham’s F12 
media. SW480, H292 (lung cancer cell), and SqCC/Y1 was grown in RPMI 1640 media. 
MCF-7 (breast cancer cell) was incubated in Dulbecco’s Modified Eagle media (DMEM). 
T98G (brain cancer cell) was maintained in EMEM media. CMT-93 (mouse coloreactal 
cancer cell) was grown in DMEM media. 3T3-L1 (mouse embryonic fibroblast, pre-
adipocyte) was cultured in DMEM with 10 % bovine calf serum.  SCC7 (mouse 
squamous cell) was maintained in MEM media. MEF (mouse embryo fibroblast) was 
grown in DMEM media. All media, except DMEM for 3T3-L1 cell line, were 
supplemented with 10% (v/v) fetal bovine serum (FBS), and 100U/ml penicillin and 100 
μg/ml streptomycin at 37 °C with 5% CO2. 
 
2.2 Molecular biology Kits 
Human colon tumor and normal adjacent tissue pairs total RNA was purchased from 
Ambion (Austin, TX). RNA isolation kit was purchased from Omega Bio-Tek (Norcross, 
GA). iScript cDNA synthesis kit was purchased from Bio-Rad (Hercules, CA). pGEM-T 
easy cloning vector, Green Taq polymerase, and in vitro translation kit were obtained 
from Promega (Madison, WI). Agarose gel extraction kit and miniprep kit were 
purchased Zymo Research (Orange, CA). The QuikChange II site-directed mutagenesis 
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kit was obtained from Stratagene (La Jolla, CA). pCR 2.1 TA TOPO cloning, pcDNA3.1 
V5-tagged TOPO and pcDNA3.1/CT-GFP-tagged TOPO expression vector were 
obtained from Invitrogen (Carlsbad, CA). Enhanced Chemiluminescence (ECL) kit for 
western blot and Chemiluminescence nucleic acid detection kit for EMSA was obtained 
from Pierce (Rockford, IL). Nuclear extract kit for EMSA was purchased from Active 
Motif (Carlsbad, CA). Primers, listed in table 3, were purchased from Operon (Pittsburgh, 
PA).  
 
2.3 Antibodies  
KLF4, RBM5, and β-Actin primary antibodies were obtained from Santa Cruz 
Biotechnology (Santa Cruz, CA). Serine/threonine phospho antibody was purchased from 
BD biosciences (San Jose, CA). Antibody for V5 was purchased from Invitrogen 
(Carlsbad, CA). Secondary antibodies for western blot and tetramethyl rhodamine iso-
thiocyanaste (TRITC) labeled secondary antibody for immunofluorescence were 
purchased from Southern Biotech (Birmingham, AL).  
 
2.4 Chemicals 
Sulindac sulfide (SS) was purchased from Calbiochem (San Diego, CA). 5-[[6-[(2-
fluorophenyl)-methoxy]-2-napthalenyl]methyl]-2,4-thiazolidinedione (MCC-555) was 
obtained as a gift from Mitsubishi Pharma Corporation (Tokyo, Japan). Rosiglitazone 
(RGZ) and Tolfenamic acid (TA) were purchased from Cayman Chemical Co (Ann 
Arbor, MI). 3,3’-diindolylmethane (DIM), and (-)-epigallocatchin-3-gallate (EGCG) 
were purchased from Sigma (St. Louis, MO). 4’,6-diamidine-2’-phenylindole 
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dihydrochloride (DAPI) for nuclear staining was obtained from Roche Applied Science 
(Indianapolis, IN). All other chemicals were purchased from Thermo Fisher Scientific 
(Pittsburgh, PA).  
 
2.5 Total RNA isolation 
Total RNA was isolated using the RNA isolation kit according to the manufacturer’s 
instructions. In case of reagent treatment such as MCC-555, rosiglitazone, TA, sulindac 
sulfide, DIM, and EGCG, the cells were grown until 60-70% confluent in 6-well plates. 
The cells were incubated with serum free media overnight, and then reagents were treated 
in serum free media for 4h or 24h. Next, the cells were washed with phosphate buffered 
saline (PBS) and harvested with 350μl of cell lysis buffer. After total RNA isolation, 
RNA concentration was measure by spectrophotometer at 260/280nm. 
 
2.6 Reverse Transcription PCR (RT-PCR) 
Total RNA (1μg) was reverse-transcribed with the iScript cDNA kit according to the 
manufacturer’s instructions. Briefly, 1 μg of total RNA was mixed with 5X iScript 
reaction mixture including reverse-transcriptase, dNTP, oligo-dT, and random primers in 
PCR tubes. The cDNA synthesis reaction was as followed; 25°C for 5min, 42°C for 
30min, 85°C for 5min, and 4°C for holding. After cDNA synthesis, 1/20 of cDNA was 
used for the template and PCR was performed using 2X Green Taq polymerase with 
primers (see Table 3).  In order to perform the PCR reaction for KLF4, the PCR condition 
was as followed; 94°C for 30 s, 55°C for 30 s, and 72°C for 2 min for 25 cycles for KLF4 
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or 20 cycles for GAPDH, which is internal control. After RT-PCR reaction, samples were 
loaded into 1.0% agarose gel with 0.5X TAE buffer (Tris-HCl/acetate/EDTA buffer) and 
ethidium bromide, which is a DNA intercalating agent, to visualize DNA under UV. The 
agarose gel was separated at 100V for 20min and the intensity of PCR bands were 
quantified by using Scion Image software (Frederick, MD). Each sample was normalized 
to the intensity value of GAPDH.    
 
2.7 KLF4 cDNA constructs 
KLF4L, KLF4M, and KLF4S cDNAs were amplified by RT-PCR using human total RNA 
from Ambion. Each KLF4 PCR bands were isolated using agarose gel extraction kit. 100 
ng of cDNAs were subcloned into pcDNA 2.1 TOPO cloning vector and then 
transformed into DH5α competent bacterial cells on Luria-Bertani (LB) plate containing 
100μg/ml ampicillin. After overnight incubation at 37°C, several single colonies were 
inoculated into LB broth with 100μg/ml ampicillin and incubated in the bacterial shaker 
at 37°C for overnight. Plasmid DNA was purified using Miniprep kit from Zymo 
Research and cDNA insert was verified by DNA sequencing. KLF4 cDNAs were 
digested with EcoR I and Hind III and then subcloned into V5-tagged-pcDNA3.1 
expression vector (Invitrogen). DNA sequence was confirmed by sequencing.  
 
 2.8 RBM5 cDNA construct 
RBM5 cDNAs were were amplified by RT-PCR using human total RNA from Ambion. 
Next, the cDNA was subcloned into pGEM-T easy cloning vector. cDNA was verified 
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sequencing. RBM5 cDNA was digested with BamH I and Xba I and then, ligated with 
pcDNA 3.1 expression vector. Subcloning procedures occurred as stated. 
 
2.9 KLF4 minigene construct 
The KLF4 minigene splicing cassette was generated by amplifying a 1.6 kb genomic 
DNA fragment from the KLF4 gene (exon-2 to exon-4) with Pfu polymerase using 
human genomic DNA (Promega, WI). KLF4 genomic fragment was subcloned into 
pcDNA3.1 CT-GFP-TOPO expression vector digested with Kpn I and Xba I sites and 
then verified by sequencing.  
 
2.10 Site-directed mutagenesis 
Point mutations of KLF4 minigene and RBM5 were produced by the site-directed 
mutagenesis kit (Stratagene, Santa Clara, CA). Briefly, the reaction mixture was as 
follow; 10 ng of template DNA, 125 ng of forward and reverse primers, dNTP, and Pfu 
polymerase. The reaction mixture was incubated under the following conditions; 94°C 
for 1 min (initial step), 94°C for 1min, 58°C for 1min, and 68°C for 9 min for 25 cycles 
for KLF4 and   68°C for 10 min for 25 cycles for RBM5. Next, 10 U of Dpn I restriction 
enzyme was added into the PCR mixture and incubated at 37°C for 1 h. Subsequently, 
1/5 sample was used for transformation into XL-1 blue bacterial competent cells. Each 





Table 3. Primer sequence for KLF4L, KLF4S, RBM5, and the KLF4 minigene 
construct.  
 
Primer Oligo sequence 
KLF4 EcoR I F 5’-CGAATTCTATGGCTGTCAGCGACGCG-3’ 
KLF4 Hind III R 5’-CCCAAGCTTTTAAAAATGCCTCTTCATGTGTAAGGC-3’ 
KLF4S F 5’-ATGGCTGTCAGCGACGCGCTG-3’ 
KLF4S R 5’-TTAAAAATGCCTCTTCATGTGTAAGGC-3’ 
mKLF4 F 5’-ATGGCTGTCAGCGACGCTCTG-3’ 
mKLF4 R 5’-AAAGTGCCTCTTCATGTGTAAGGC-3’ 
GAPDHF 5'- GGGCTGCTTTTAACTCTGGT-3’ 
GAPDHR 5’-TGGCAGGTTTTTCTAGACGG-3’ 
KLF4 mini F 5’-TGGCTGTCAGCGACGCGCTGCTCC-3’ 
KLF4 mini R 5’-CTGTGTGGGTTCGCAGGTGTGCCTTG-3’ 
KLF4miniMF 5’- GTCTCTCCCGCCCTGTTCTTGCAGCGCTTGG-3’ 
KLF4miniMR 5’-CCAAGCGCTGCAAGAACAGGGCGGGAGAGAC-3’ 
RBM5 BamH I F 5’-CCGGATCCGGGACAATGGGTTCAGACAAAAGAGTG -3’ 








2.11 Transient transfection and luciferase reporter assays 
Transient transfection was performed using PolyJet DNA in vitro transfection reagent 
from SignaGen (Ijamsville, MD), according to the manufacturer’s instruction. Briefly, 
HCT-116 cells were plated in 12-well plates at 105 cells per well and were grown for 16 h. 
Plasmid mixture containing PAI-1, cyclin D1, or TOPFlash luciferase constructs, and 
pRL–null (Promega, WI) were transfected and the cells were fed fresh medium (McCoy’s 
5A medium with 10% FBS) overnight. After cell harvest using 1X luciferase lysis buffer, 
luciferase activity was determined and normalized to the pRL-null luciferase activity 
using a dual luciferase assay kit (Promega, WI). 
 
2.12 siRNA experiment 
RBM5 siRNA was obtained from Santa Cruz Biotechnology (Santa Cruz, CA). siRNA 
treatment was performed using TransIT-TKO transfection reagent from Mirus Bio 
(Madison, WI). According to manufacture protocol, HCT-116 cells were plated into 6 
well plates at 106 per well and incubated for 16h. Next, the reaction mixture, containing 
10 μl TKO reagents in 250 μl serum free McCoy 5A media, was incubated for 5 min at 
RT and then, 100 nM RBM5 siRNA was added with additional 20 min incubation. The 
siRNA mixture was directly added into HCT-116 cells and incubated 48h. 
 
2.13 Establishment of stable cell line  
HCT-116 cells were plated in 6-cm plates and transfected with KLF4 minigene or 
CONTROL vector (pcDNA3.1/V5-His-TOPO/LacZ) using LipofectAMINE (Invitrogen, 
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Carlsbad, CA), according to the manufacturer‘s protocol. After 24 h, the cells were then 
transferred to a 10 cm plate with G418 (800μg/ml) (Stratagene). Selection with G418 was 
carried out for 3 weeks and then RT-PCR was carried out to check the stable cell lines. 
 
2.14 Western blot analysis 
The cells were grown to 60-80% confluence in 6-cm plates followed by 24 h treatment in 
the presence of indicated compounds. The cells were then washed once with PBS and 
harvested using ice-cold RIPA buffer (PBS, 1% NP-40, 0.5% sodium deoxycholate, 0.1% 
SDS) supplemented with protease inhibitors (1 mM PMSF, 5 μg/ml aprotinin and 5 
μg/ml Leupeptin) and phosphatase inhibitors (1 mM Na3VO4 and 1 mM NaF). Cell 
lysates were collected and kept on ice for 30 minutes followed by protein collection by 
quick centrifugation. The protein concentration was determined by BCA protein assay 
(Pierce, Rockford, IL) using bovine serum albumin (BSA) as the standard. Equal aliquots 
of 30 μg protein were boiled in 2X loading buffer (0.1 M Tris-Cl, pH 6.8, 4% SDS, 0.2% 
Bromophenyl blue, 20% glycerol) for 5 min, and then separated by SDS-PAGE (8-14% 
gels), followed by transfer to nitrocellulose membranes (Osmonics, Minnetonka MN) for 
1 h. The blots were blocked for 1 h with 5% skim milk in TBS/Tween 0.05% (TBS-T), 
and probed with a specific primary antiserum in tris buffered saline (TBS) containing 
0.05% Tween-20 (TBS-T) and 5% non-fat dry milk at 4°C overnight. After washing with 
TBS-T, the blots were treated with horseradish peroxidase-conjugated secondary 
antibody for 1 h and washed several times. Proteins were detected by the enhanced 




2.15 Nickel pull-down analysis 
HCT-116 cells were transiently transfected with either RBM5 expression vector 
(pcDNA3.1/V5-His-TOPO/RBM5) or control vector (pcDNA3.1/V5-His-TOPO/LacZ) 
using Lipofectamin2000 (Invitrogen) according to the manufacturer‘s protocol. The 
RBM5 proteins containing six histidine residues at their C-termini were purified using 
ProBond nickel-chelating resin (Invitrogen), under native condition buffer (50 mM 
NaH2PO4/pH 8.0, 500 mM NaCl, 1 mM PMSF, 1 μg/ml aprotinin, 1 μg/ml leupeptin), 
and subsequently incubated with 50 μL of ProBond Resin (50% Slurry in 20% ethanol) 
for 30 min at 4°C. Beads were then washed three times, boiled for 5 min, and loaded on 
SDS/PAGE for Western blot analysis.  
 
2.16 Immunofluorescence 
Immunofluorescence was performed as described previously (Lee et al 2008). Briefly, the 
cells were washed with PBS, fixed with 4% paraformaldehyde for 30 min, and washed 
three times with PBS for 5 min. The cells were incubated with anti-V5 primary antibody 
overnight at 4̊C and then with goat anti -mouse TRITC conjugate for 1 h at room 
temperature in the dark. The cells were stained with 0.5 mg/ml of DAPI for 10 min to 
counterstain the nucleus. The expression of proteins was detected using a Nikon Eclipse 
E600 fluorescence microscope. The TIF images were captured using QCapture software 
version 2.66.4 with X400 magnification. 
 
2.17 Electrophoretic mobility shift assay (EMSA) 
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KLF4L and KLF4S proteins were prepared following the manufacturer’s protocols 
(Promega, WI) using the KLF4L and KLF4S pGEM-T easy construct. Synthetic 
oligonucleotides corresponding to the KLF4 binding site contained the following 
sequence: 5'-ATGCAGGAGAAAGAAGGGCGTAGTATCTACTAG-3' (Shields and 
Yang 1998). EMSA was performed using a Light Shift Chemiluminescent EMSA kit 
following the manufacturer’s protocols (Pierce, IL). Briefly, biotin-labeled 
oligonucleotide (10 nM) was incubated with purified nuclear extract or in vitro translated 
KLF4 (5 μg), 1X binding buffer, 2.5% glycerol, 5 mM MgCl2, 50 ng/μl Poly (dI·dC), and 
0.05% NP-40 at room temperature for 20 min. For competition assay, nuclear extracts 
were preincubated with the unlabeled oligonucleotide (10X and 100X) for 10 min. DNA-
protein complexes were resolved by 5% nondenaturing polyacrylamide gel and 
transferred to a nylon membrane, followed by chemiluminescent nucleic acid detection 
according to the manufacturer’s protocols. 
 
2.18 Human normal and adjacent tumor tissues 
These samples were generously provided by Dr. Joo-Heon Yoon (Yonsei University, 
Korea). This study was approved by the Institutional Review Board of Yonsei University 
Health System, and all specimens were supported by the Colon Cancer Specimen Bank 
from the National Research Resource Bank Program of the Korea Science and 
Engineering Foundation in the Ministry of Science and Technology. For comparison, 
three histologically normal colons and three adjacent to colorectal adenocarcinomas were 





2.19 Statistical analysis  






















Alternative splicing of KLF4 










3.1 KLF4 splicing variants in human and mouse cancer cells  
To investigate the expression of KLF4 mRNA in human and mouse cell lines, we 
performed RT-PCR with specific primers covering the coding region of KLF4 mRNA. 
The results revealed that at least three KLF4 splicing variants were produced in human 
colorectal and non-colorectal cancer cell lines (Figure 3-1A). Hereafter, we designate the 
KLF4 splicing variants as large KLF4 (KLF4L), medium KLF4 (KLF4M), and small 
KLF4 (KLF4S). The highest amount of KLF4L mRNA expression was observed in LoVo 
cells, and the lowest amount of KLF4L was in A549 and PC-3 cells. However, all the 
cancer cell lines showed a similar amount of KLF4S mRNA expression. We also tested 
KLF4 splicing variants in mouse cell lines by RT-PCR (Figure 3-1B). RT-PCR analysis 
revealed that the mouse KLF4 gene generates two splicing variants: mKLF4L and 
mKLF4S, indicating that alternative splicing of KLF4 is not only seen in humans but also 
in mice.  
Since KLF4 protein expression was significantly decreased in gastric and colorectal 
cancer (Dang et al 2000a, Wei et al 2005, Zhao et al 2004), we determined whether KLF4 
splicing is different in normal and adjacent tumor tissues. Therefore, we attempted to 
investigate KLF4L and KLF4S mRNA expression patterns by RT-PCR in human colon 
normal and tumor tissue. KLF4S transcripts were significantly detected in both normal 
and tumor samples, but the KLF4L transcript level was significantly reduced in tumors 





Figure 3-1. KLF4 splicing variants in different cell lines. (A) Three major human 
KLF4 splicing variants, KLFL, KLFM, and KLFS, were detected by RT-PCR. RT-
PCR analysis was performed with total RNA extracts from human cancer cell lines. 
Colorectal cancer cells are HCT-116, SW480, HT-29, and LoVo. Non-colorectal 
cancer cells are H292 (lung), A549 (lung), MCF7 (breast), SqCC/Y1 (head and neck), 
PC3 (prostate), and T98G (brain). (B) RT-PCR analysis of KLF4 splicing variants 
in mouse cell lines. CMT-93 is a mouse rectal cancer cell. Mouse non-colorectal 
cancer cells are 3T3-L1 (fibroblast), SCC7 (squamous cell carcinoma), and mouse 










Figure 3-2. KLF4L, KLF4M, and KLF4S in human normal colon and tumor tissue 
samples. Human normal tissue (N1) and adjacent human tumor tissue RNAs (T1) 
were purchased from Ambion. N2-4 and T2-4 total RNAs were isolated from three 
colorectal cancer patients. KLF4 transcripts were analyzed by RT-PCR, and PCR 
products were confirmed by sequencing. Quantitative analysis from the RT-PCR is 
shown in the graph (Right). Error bars indicate standard deviation. The formula for 





3.2 KLF4S was produced by exon skipping   
To obtain further information of KLF4 splicing variants in humans and mice, we cloned 
individual RT-PCR products and verified them by sequencing. Sequence analysis 
revealed that the human KLF4S transcript encodes a 154 amino acid protein by exon 
skipping (Figure 3-3). The skipped KLF4 exon-3 is the biggest exon, containing a 
transcription activation domain and an inhibitory domain (Wei et al 2006). Interestingly, 
human KLF4S contains the nuclear localization signal (NLS) and three C2-H2 zinc finger 
domains (Figure 3-4). In case of mouse KLF4, mKLF4S was produced by combination of 
5’ splice site and 3’ splice site alternative splicing patterns. Also, mKLF4S is missing a 
signal peptide and one zinc finger domain (Figure 3-5). It is possible that mKLF4S could 
not translocate to the nucleus compared to human KLF4S (Figure 3-6).  
Another KLF4 splicing variant KLF4M is produced by the alternative 3’ splice site mode. 
However, KLF4M contains a premature termination codon that probably leads to 
nonsense-mediated decay (NMD) (Brogna and Wen 2009).  
Sequence analysis suggests that human KLF4S might be able to translocate to the nucleus 
and bind to KLF4 target gene as an antagonist. Genomic DNA sequence analysis of the 
5’ and 3’ splice site regions between human and mouse KLF4 revealed that the second 
intron 3’ splice site may be important to exon skipping as a consequence of different 











Figure 3-3. KLF4S is produced by exon skipping. Schematic representation of 
human and mouse KLF4 splicing variants. Human KLF4L and KLF4S encode 513 
and 154 amino acids, respectively, by exon skipping. KLF4M contains a premature 
stop codon and could be degraded by the NMD pathway. Mouse KLF4S (mKLF4S) 
are produced by a combination of the 5’ and 3’ alternative splicing sites. The open 
box indicates the 5’ and 3’ untranslated region (UTR). The blue box represents the 









Figure 3-4.  Amino acid sequence alignment of human KLF4L and KLF4S. Sequence 
alignment was done by using Clustral W2 (http://www.ebi.ac.uk/Tools/clustalw2). 
The number indicates amino acid length of KLF4. Nuclear localization signal (NLS) 









Figure 3-5.  Amino acid sequence alignment of mouse KLF4L and KLF4S. Sequence 
alignment was done by using Clustral W2 (http://www.ebi.ac.uk/Tools/clustalw2). 
The number indicates amino acid length of KLF4. Nuclear localization signal (NLS) 









Figure 3-6.  Amino acid sequence alignment between human KLF4S and mouse 
KLF4S. Sequence alignment was done by using Clustral W2 
(http://www.ebi.ac.uk/Tools/clustalw2). The number indicates amino acid length of 
KLF4. The blue box indicates human KLF4S N-terminal region which encoded by 
exon 1 and 2. The red box represents human KLF4S C-terminal region. In mouse 
KLF4, red letters and blue letters indicate amino acids joined by combination of 5’ 





3.3 Mutation of the 3’ splice site in the second intron decreased 
the KLF4 splicing ratio  
To investigate whether the 3’ splicing site of the second intron affects human KLF4 exon 
skipping, we established the KLF4 minigene system (Figure 3-8A). The minigene system 
is a powerful tool to investigate the cis-acting element or trans-acting factor involving the 
alternative splicing event of the multiple-exon gene (Cooper 2005). The human KLF4 
genomic fragment, from KLF4 exon-2 to exon-4 containing intron-2 and intron-3, was 
subcloned into pcDNA 3.1 CT-GFP vector. Alterative splicing was examined by RT-
PCR. In addition, three nucleotides on the 3’ splicing site of intron-2 in the human KLF4 
gene were mutated to the mouse sequence (Figure 3-7). The wild type and mutated 
minigenes were individually transfected into HCT-116 cells and alternative splicing was 
determined by RT-PCR using vector-specific primers to discriminate endogenous KLF4 
transcripts. The KLF4 minigene system effectively produced the alternative splicing 
variants KLF4L and KLF4S, but not KLF4M. Mutation of the 3’splice site in the second 
intron significantly suppressed the KLF4 splicing ratio, compared to wild type KLF4 in 
the minigene system (Figure 3-8B). This suggests that the 3’ splicing site of the second 













Figure 3-7. Sequence comparison of the splicing border regions between human and 
mouse KLF4 genes. Blue letters indicate the 5’ and 3’ splice site and “-a-” designates 









Figure 3-8. KLF4 3’splice site suppressed alternative splicing of the KLF4 minigene. 
(A) Schematic diagram of the KLF4 minigene, which contained the KLF4 exon 2-4 
and intron 2-3. Three nucleotides on the 3’ splice site within the second intron of 
human KLF4 were substituted to the mouse KLF4 3’splice site, indicated by red 
colors and a red line on the diagram. Arrows indicate primers for determining the 
splicing rate of the KLF4 minigene. (B) Mutation of the KLF4 3’splice site 
suppressed alternative splicing of the KLF4 minigene. The KLF4 minigene was 
transfected into HCT-116 cells and RT-PCR was performed. The graph represents 




3.4 Double 3’ splice sites contribute to the in-frame transcripts 
of KLF4 
One of the interesting features of KLF4 sequences is that the KLF4 carries a unique 
double 3’ splice sites (“agag”) on the intron-3 (Figure 3-9). The exon-3 inclusion on 
KLF4L utilizes the first “ag”, whereas the exon inclusion on KLF4S utilizes the second 
“ag”. This accurate process prevents the frame shift, resulting in identical C-terminal 
sequences in both KLF4L and KLF4S forms. For example, if KLF4L uses the second “ag” 
for connecting exon-3 and exon-4, this transcript produces 397 a.a rather than 513 a.a 
KLF4 protein by premature stop codon. On the contrary, if KLF4S utilizes the first “ag” 
for joining of exon-2 and exon-4, the transcript will be 109 a.a rather than 154 a.a protein. 
This is not only seen in human colorectal cancer cell lines, but also seen in KLF4L and 
KLF4S splicing variants from human tissue samples (Figure 3-2). To demonstrate the 
majority of 3’ splice sites of the KLF4 exon-3 exclusion, RT-PCR products were 
carefully investigated by the direct PCR sequencing and minor usage of 3’ splice sites 
can be abolished by using this method (Figure 3-9B).  
A double 3’ splicing site (agag) in FAS gene (CD95) from autoimmune 
lymphoproliferative syndrome (ALPS) patients has been reported (Roesler et al 2005). 
However, the double 3’ splice site in KLF4 gene is a natural sequence rather than a point 
mutation as seen in FAS gene. Therefore, further studies are necessary to investigate the 






Figure 3-9. Double 3’ splice sites on intron-3 of KLF4. (A) The double 3’ splice sites 
are indicated by red arrows; L is the 3’splice site for KLF4L and S is for KLF4S. (B)  
Sequencing data for the exon joining region on the KLF4S. KLF4L contains “ag”, 
indicating red letters and red arrow shows the border between exon-3 and exon-4. 
Alternative spicing of KLF4S produces without “ag” on border between exon-2 and 




3.5 RBM5 altered the KLF4 splicing ratio  
Recent studies showed that RBM5 regulates alternative splicing of FAS and caspase 2 
mRNA (Bonnal et al 2008, Fushimi et al 2008). Therefore, we questioned whether KLF4 
alternative splicing is also controlled by RBM5. RBM5 expression vector and KLF4 
minigene were co-transfected into HCT-116 cells and then alternative splicing was 
examined by RT-PCR. Overexpression of RBM5 significantly increased KLF4 
alternative splicing ratio, suggesting that RBM5 controls KLF4 splicing (Figure 3-10A).  
On the other hand, the down-regulation of RBM5 by siRNA treatment decreased the 
KLF4 splicing ratio (Figure 3-10B). Based on these results, RBM5 could be a major 
mediator to control KLF4 alternative splicing. 
 
3.6 Sulindac sulfide (SS) restores KLF4L in HCT-116 cells via 
RBM5 dephosphorylation  
Previously, we reported that various nonsteroidal anti-inflammatory drugs (NSAIDs), 
PPARγ ligands, and dietary compounds have anti-tumorigenic effects in colorectal cancer 
cells (Sukhthankar et al 2008, Yamaguchi et al 2006). Therefore, we tested whether 
treatment with these compounds affects alternative splicing of KLF4. Among those, SS 
treatment (10 μM) significantly increased endogenous KLF4L and KLF4M in HCT-116 
cells (Figure 3-11A). Using the KLF4 minigene system, we found that SS and MCC-555 
suppress the splicing ratio of KLF4 in both HCT-116 and LoVo cells (Figure 3-11B), 
respectively; however, RBM5 overexpression increased splicing of the KLF4 minigene in 
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both cell lines. These results indicate a pivotal role of RBM5 in KLF4 alternative splicing 
in both cells. However, SS and MCC-555 may not be enough to fully increase KLF4L 
forms in the presence of RBM5.  
Previous report also suggested that RBM5 is a phospho-protein; however, there is no 
evidence connecting RBM5 phosphorylation and splicing activation onto its target pre-
mRNA (Ekim et al 2003). To test SS effects on the phosphorylation of RBM5, we 
performed nickel pull-down followed by western blot using the phospho-serine/threonine 
antibody. After SS treatment, total serine/threonine phosphorylation of RBM5 was 
decreased in a dose-dependent manner, whereas expression of total RBM5 was not 
changed (Figure 3-12A). Additionally, a point mutation of RBM5 at serine 69 (S69A) 
showed significant inhibition of KLF4 minigene splicing (Figure 3-12B). Therefore, our 
finding suggests that phosphorylation of RBM5 plays a role in KLF4 exon skipping and 
SS facilitates dephosphorylation of RBM5, leading to diminished exon skipping. This 









Figure 3-10. Overexpression or knockdown of RBM5 alters the KLF4 splicing ratio. 
(A) Overexpression of RBM5 increases alternative splicing of KLF4. KLF4 
minigene and V5-tagged RBM5 construct were transfected into HCT-116, and then 
the KLF4 splicing ratio was examined by RT-PCR analysis. Overexpression of 
RBM5 was confirmed by Western blot analysis using the anti-V5 antibody. (B) 
Knockdown of RBM5 by siRNA decreases the KLF4 splicing ratio. RBM5 
knockdown was confirmed by Western blot with RBM5 antibody. The bar graphs 
on the right represent mean value and the error bar indicates SD from three 




Figure 3-11. SS suppresses alternative splicing of KLF4. (A) HCT-116 cells were 
starved in serum free-media overnight and then incubated for 4 h with PPAR-γ 
ligands, NSAIDs, and dietary compounds; RNA was isolated for RT-PCR analysis.  
10 μM SS treatment significantly restored endogenous KLF4L transcripts (V, 
vehicle; MCC, 10μM MCC-555; RGZ, 10μM Rosiglitazon; TA, 30μM Tolfenamic 
acid; SS, 10μM Sulindac sulfide;  DIM, 10μM 3,3'-diindolylmethane;  EGCG, 10μM 
epigallocatechin gallate). Gapdh is the loading control. (B) RBM5 overexpression 
enhanced KLF4 alternative splicing under the KLF4 minigene system. The KLF4 
minigene was transiently transfected for 24 h into HCT-116 cells or LoVo cells and 
then the cells were treated with vehicle (V), 5 µM MCC-555 (M), and 10 µM SS (S) 





Figure 3-12. Dephosphorylation of RBM5 altered KLF4 splicing. (A) 
Phosphorylation of RBM5 was inhibited by sulindac sulfide treatment. His-tag 
RBM5 was pulled down by Ni-agarose bead and western blot was performed with 
phospho-serine/threonine antibody. Actin was the loading control. (B) RBM5 
mutant (S69A) could not facilitate the KLF4 splicing. The wild type RBM5 and 
mutant RBM5 construct were cotranfected with the KLF4 minigene into HCT-116 
and the splicing ratio measured by RT-PCR. The bar graphs on the right represent 





3.7 Biological roles of KLF4S  
Significant amounts of KLF4S mRNA and sequence analysis results suggest that KLF4S 
could have particular biological activities in the cell. To elucidate biological function of 
KLF4S in human colorectal cancer cells, we overexpressed KLF4S into HCT-116 cells. 
The V5-tagged KLF4S was detected by Western blot analysis. The extra bands of 
overexpression of KLF4L could be degraded forms as previously observed (Shie et al 
2000). In addition, endogenous KLF4L expression was examined by using the anti-KLF4 
antibody, and all the transfected cells expressed the expected protein as assessed by 
Western blot (Figure 3-13). 
Based on our sequence analysis, we determined KLF4S could be located in the nucleus 
since KLF4S contained a nuclear localized signal (Figure 3-4). To identify the subcellular 
localization of KLF4S, we performed immunofluorescence using the anti-V5 antibody in 
HCT-116. The lacZ protein, as a control, was predominantly expressed in the cytoplasm, 
and KLF4L was highly expressed in the nucleus.  However, KLF4S was detected both in 
the cytoplasm and nucleus (Figure 3-14A). To verify our immunofluorescence data, we 
isolated nuclear and cytoplasm fractions from overexpressed KLF4 cell lysates and then 
performed the Western blot with the V5-antibody. We found that lacZ was predominantly 
expressed in the cytoplasm, whereas KLF4L was predominantly expressed in the nucleus, 
consistent with the immunofluoroscence results; however, KLF4S was expressed in both 









Figure 3-13. Western blot analysis of human KLF4L and KLF4S transiently 
transfected into HCT-116. After 24h Transfection, the cells were harvested with 
RIPA buffer. LacZ was used for the control experiment. Overexpressed proteins 
were detected by anti-V5 antibody (top). Endogenous KLF4 expression was detected 









Figure 3-14. KLF4S has cellular localization and DNA binding activity similar to 
KLF4L. (A) Localization of V5-tagged overexpressed KLF4L and KLF4S in HCT-
116 cells was visualized by fluorescence microscope. The nucleus was stained by 
DAPI and TRITC for LacZ, KLF4L, and KLF4S. (B) Localization of KLF4L and 
KLF4S was confirmed by Western blot analysis using cytosol fraction (C) and 





Finally, DNA binding activity of KLF4S was investigated by the electrophoretic mobility 
shift assay (EMSA) with biotin-labeled oligonucleotides for the KLF4 binding element 
(Shields and Yang 1998). Both KLF4L and KLF4S were obtained from the in vitro 
translation method and an apparent DNA-protein complex was observed (Figure 3-15). In 
addition, the V5-tagged KLF4/DNA complex was recognized on the same membrane by 
Western blot. These results suggest that KLF4S is localized in the nucleus and binds to 
the KLF4 binding element. 
Cyclin D1 is a well known KLF4 target gene (Shie et al 2000). To elucidate KLF4S 
transcription activation or repression activity, a -163/+130 cyclin D1 promoter construct 
containing a single KLF4 binding site (Castro-Rivera et al 2001) was cotransfected with 
either KLF4L, KLF4S, or LacZ into HCT-116. As previously reported, overexpression of 
KLF4L suppressed luciferase reporter gene activity (Shie et al 2000). However, KLF4S 
did not repress cyclin D1 promoter activity, compared to KLF4L (Figure 3-16). The 
Plasminogen activator inhibitor-1 (PAI-1) promoter containing four KLF4 binding sites 
was also used to test KLF4s activity (Chen et al 1998). Cotransfection of KLF4L and the -
884/+71 PAI-1 promoter construct repressed reporter gene transcription. However, KLFS 
slightly inhibited reporter gene transcription compared to the control. These results 
suggested that KLF4S is an inactive form of KLF4L.  
A recent study showed that KLF4 interacts with the C-terminal of β-catenin, and 
inhibition of β-catenin signaling is required in both the N-terminal and C-terminal of the 
KLF4 domain (Wang et al 1996). KLF4S contains sufficient domains to bind with β-
catenin, but not to inhibit β-catenin activity. Therefore, we tested TOPFlash reporter 
construct activity together with KLFL and KLFS (Figure 3-17A). As expected, KLF4L 
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inhibited TOPFlash activity; however, KLFS rather enhanced β-catenin signaling in HCT-
116 cells. To identify whether KLF4S physically interacts with β-catenin, KLF4L and 
KLF4S was overexpressed in HCT-116 followed by Ni-agarose pull-down experiment 
(Figure 3-17B). Western blot results using β-catenin antibody showed that both KLF4L 
and KLF4S strongly bind to β-catenin. Therefore, KLF4S could modulate activity of 
KLF4L in Wnt/β-catenin signaling pathway in colorectal cancer. 
Together with other results, KLF4S forms may inactivate KLF4L’s tumor suppressor 
activity in colorectal tumorigenesis. This is evidence that alternative splicing may provide 
an important mechanism for the regulation of tumorigenesis in the human colorectal 
tumorigenesis. 
 
3.8 Summary  
Based on our results, we propose a model of the KLF4 alternative splicing mechanism 
(Figure 3-18), in which KLF4S is produced by exon skipping and antagonize KLF4L 
activities, and subsequently enhances tumorigenesis. Phosphorylation of RBM5 also 
enhances KLF4 alternative splicing toward KLF4S; however, SS treatments repress KLF4 
splicing processes by dephosphorylation of RBM5. Therefore, KLF4 splicing variants 






Figure 3-15. Electrophoretic mobility shift assay (EMSA) analysis of KLFL and 
KLF4S. (A) KLF4S is able to bind to the same KLF4L DNA binding site. EMSA 
analysis was performed using in vitro translated protein extracts. Western blot 
analysis evaluated recombinant KLF4 protein using V5 antibody to detect the DNA-
protein complex followed by treatment of the stripping buffer (Thermo Scientific) 
on the same membrane. (B) EMSA was performed using nuclear extracts to confirm 
the DNA binding activity of KLF4L and KLF4S.  The competition of the DNA 









Figure 3-16. KLF4S antagonizes KLF4L activity. KLF4S suppresses KLF4L activity 
on the cyclin D1 and PAI-1 promoter. The upper diagram indicates cyclin D1 and 
PAI-1 luciferase reporter construct containing the KLF4 binding site, indicated by 
an arrowhead. KLF4L and KLF4S were co-transfected with cyclin D1 or PAI-1 
construct into HCT-116 cells. Luciferase activity was measured as a ratio of firefly 
luciferase signal/renilla luciferase signal and is shown as mean ± SD of fold change 









Figure 3-17. KLF4S interacts with β-catenin. (A) KLF4S is not able to inhibit 
TOPFlash reporter activity. The TOPFlash luciferase reporter construct was co-
transfected with LacZ, KLF4L, or KLF4S into HCT-116 cells. The represented 
results were independently performed three times. Error bars indicates SD. (B) 
Interaction between KLF4S and β-catenin was confirmed by Ni-pull down 









Figure 3-18. Model of alternative splicing of KLF4 and regulation by RBM5. In case 
of normal cells, KLF4L is associated with cell apoptosis, proliferation, and 
differentiation. The phosphorylated RBM5 facilitates KLF4 alternative splicing and 
generates KLF4S, which inhibit KLF4L functions. In the presence of SS, the RBM5-
mediated alternative splicing of KLF4 is inhibited and KLF4L mRNA production is 




























4.1 Alternative splicing occurs in KLF4 transcription. 
Alternative splicing is an important post-transcriptional regulation mechanism to control 
normal and cancer cell processes including apoptosis and tumorigenesis. It has been 
reported that KLF4 protein level is significantly decreased in adenomas from FAP 
patients (Dang et al 2000a, Ton-That et al 1997) and, KLF4 mRNA level is decreased in 
adenomas and carcinomas, compared to normal tissue (Shie et al 2000). To our 
knowledge, this is the first report that alternative splicing (exon skipping) is observed 
during tumorigenesis in the KLF4 gene. Three major variants of KLF4 are found in 
cancer cells: KLF4L, KLF4M and KLF4S (Figure 3-1). In addition, KLF4S is generated by 
exon skipping and we could detect KLF4S mRNA in most cancer and normal cells. This 
obervation was seen in normal colon tissues when RT-PCR was performed using colon 
tissues (Figure 3-2). However, the level of KLF4L mRNA was barely detected in both 
cancer cell lines and human colon cancer tissue samples. Therefore, alterative splicing is 
a major contributor for regulating KLF4L mRNA level in tumorigenesis.  
 
4.2 KLF4S antagonizes with KLF4L biological activity.   
To examine the biological function of KLF4S, we overexpressed KLF4S in human 
colorectal cancer cells. Interestingly, KLF4S can translocate to the nucleus and bind to the 
KLF4 binding site on KLF4 target genes including cyclin D1 and PAI-1, and inhibit β-
catenin signaling (Figure 3-16 and 3-17). Particularly, Wnt/β-catenin signaling is crucial 
for the maintaining and organizing of the human intestinal epithelium (Pinto et al 2003). 
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Recently, KLF4 directly interacts with β-catenin as well as T cell factor 4 (TCF4) to 
inhibit β-catenin and p300/CBP complex (Evans et al 2010). In Figure 3-17B, KLF4S 
directly interacts with β-catenin, suggesting KLF4S may play a pivotal role in 
tumorigenesis. Since KLF4 is a transcription factor and controls many genes involved in 
cell proliferation and differentiation, localization of KLF4S in the nuclei implies 
inhibition of KLF4 transcriptional activity not only in tumorigenesis, but also in 
differentiation. Indeed, KLF4 has been known to be involved in stem cell differentiation 
(Guo et al 2009). Further investigation is required to determine the biological 
significance of KLF4S in cell differentiation.   
 
4.3 KLF4 splicing profile can be a useful diagnostic tool in 
human colorectal cancer. 
KLF4L and KLF4S splicing variants were examined in human normal and tumor tissues 
by RT-PCR (Figure 3-2). It is interesting that all the normal tissues, but not adjacent 
tumor tissues, produced KLF4L and KLF4M. This is consistent with our hypothesis that 
the 3’ splicing site in the second intron plays an important role in the KLF4 splicing 
mechanism. Based on our sequence analysis, human and mouse KLF4 showed different 
3’ splice sites on the second intron, generating different splicing variants (Figure 3-8). It 
is possible that a weak 3’ splice recognition site affects alternative splicing of mKLF4, 
because the full or partial exon-3 is found in both mKLF4L and mKLF4S. Therefore, we 
developed the KLF4 minigene system and mutated the 3’ splice site of intron-2. As 
expected, the substitution of the 3’ splice recognition site from human to mouse KLF4 
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sequence suppressed the KLF4 splicing ratio (Figure 3-7). In addition, 3’ splice site on 
the inton-3 contains the unique double “agag” sequence which showed the exon skipping 
dependent manner (Figure 3-9). Based on sequence analysis from human colon normal 
and tumor tissue sample, KLF4L utilizes the first “ag” and KLF4S uses the second “ag”, 
which produces the same peptide sequences beyond Exon 3. This makes it difficult to 
generate a specific antibody for KLF4S peptide. However, if we generated a specific 
antibody based on this study, taken together with the identification of mutation at the 
splicing site, the KLF4 splicing profiles between normal and tumor samples could be 
used for diagnostic and/or prognostic markers for colon cancer in the future. 
 
4.4 RBM5 binding site on the KLF4 mRNA   
The identification of cis-acting elements (e.g. exonic splicing enhancer element and 
intronic splicing enhancer element) and trans-acting elements within pre-mRNA of KLF4 
may give us insights into the relationship between the alternative splicing and 
tumorigenesis. To identify RBM5 binding sites on the intron-2 of KLF4, we performed 
several different experiments for RNA-protein interactions including RNA 
immunoprecipitation assay, RNA gel shift assay, and biotin labeled-RNA pull-down 
assay. Unfortunately, we could not find the specific RBM5 binding site on intron-2. It is 
thought that RBM5 may not directly bind to a specific sequence or other cis-acting 
elements located in a distant region may be required to provide optimal binding of RBM5 
to the RNA sequence. To screen a potential RBM5 binding site on the KLF4 exon-3 
which is excluded by the exon skipping, we analyzed sequence using the RESCUE-ESE 
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database (http://genes.mit.edu/burgelab/rescue-ese/). There are several potential ESE 
sequences to investigate for identification of RBM5 biding site using RNA gel shift assay 
and RNA-Chip assay. Since there is no conserved RBM5 binding sequence being 
identified, we cannot exclude the possibility that RBM5 may affect splicing without 
direct binding to the RNA sequences. 
 
4.5 Therapeutic aspects of KLF4 splicing    
Many pharmacological approaches have proposed the use of conventional drug therapy; 
oligonucleotide-mediated and RNA-based therapies could be valuable clinical 
applications for the alternative splicing-dependent human disease (Garcia-Blanco et al 
2004). We screened dietary compounds and the following conventional drugs to examine 
whether they affect alternative splicing of KLF4: PPARγ ligands and NSAIDs. 
Endogenous KLF4L levels were especially increased by SS, a nonselective 
cyclooxygenase inhibitor: SS facilitates the dephophorylation of RBM5, which leads to 
inactive RBM5. Although the detailed mechanisms need to be elucidated, this is the first 
report suggesting that SS, a known colorectal cancer inhibitor, affects alternative splicing 
through the alteration of the spliceosome complex. However, a direct kinase for 
phosphorylation of RBM5 is still unknown. There are some reports showed that SR 
proteins are phosphorylated to have an effect on RNA-protein interaction and alternative 
splicing (Duncan et al 1997, Xiao and Manley 1997). So far, several kinases have been 
reported to phosphorylate SR proteins, including SR protein kinase (SRPK) family and 
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Cdc2-like kinase (Clk/Sty) family (Cao et al 1997, Jiang et al 2009, Mathew et al 2008, 
Ngo et al 2008, Zhong et al 2009). Possibly, SS is potential inhibitor of these kinases.  
In contrast, RBM5 phosphorylation could be dephosphorylated by protein phosphatase 1 
(PP1). Protein serine/threonine phosphatases or phosphoprotein phosphatases are Mg2+ 
dependent enzymes. Especially, PP1 is a major phosphatase in this family and very 
conserved protein in eukaryotes (Ceulemans and Bollen 2004). PP1 is associated with 
regulation of diverse cellular processes including cell signal transduction, stress response, 
protein synthesis, cell cycle arrest, and apoptosis (Ceulemans and Bollen 2004, Kwiek et 
al 2006). Moreover, PP1 is involved in alternative splicing by dephosphorylation of SR 
protein (Massiello and Chalfant 2006). Although there is no evidence that RBM5 is a 
target protein of PP1, SS may affect phosphatase activity of PP1 to regulate 
dephosphorylation of RBM5.  
More than 100 different proteins are involved in spliceosome complex recognition of the 
exon-intron boundary, and dozens of serine-arginine factors enhance or repress the 
alternative splicing process (Ghigna et al 2008). However, effects of conventional drugs 
in the spliceosome complex and splicing process are not known.  
 
4.6 Future directions for alternative splicing in cancer     
Importance of alternative spicing in cancer research is emphasized by many studies 
(Srebrow and Kornblihtt 2006, Venables 2004, Venables et al 2009, Wang and Cooper 
2007). Abnormal alternative splicing is caused by mutations in cis-acting elements 
including splicing enhance (ESE and ISE), and silencer (ESS and ISS). Furthermore 
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mutations or post-translational modification (phosphorylation, acetylation, etc) on the 
trans-acting factor RNA binding protein affect alternative splicing events. Therefore both 
cis-acting elements and trans-acting factors can change mRNA splicing profile.  
Recent sequencing technology was significantly improved to apply investigation of 
splicing profile by whole transcripts sequencing, so called next-generation sequencing or 
highthough put sequencing (Marguerat et al 2008, Xiao and Lee 2010). Currently, 454 
GS FLX Titanium (Roche) can read 400-600 million bp per single running and SOLiD 
system (Applied Biosystem) can generate 15 Giga bp with 50 nt long reads. Using this 
system the entire mRNA profile, in other words “transcriptome”, can be monitored. 
Therefore, thousands of novel splicing variants by alternative splicing could be 
discovered. Moreover, cancer specific alternative splicing profile can be indentified by 
using combination of next-generation sequencing technique and systematic data analysis 
algorithm.          
Another advanced technology for alternative splicing is a cross-linking and 
immunoprecipitation (CLIP) combined with high-throughput sequencing (HITS) 
technique (Licatalosi and Darnell 2010). CLIP method is usually applied for RNA-
protein interaction study. Briefly, RNA-protein complex is covalently cross-linked by 
UV-irradiation, then RNA-protein complex is purified by immunoprecipitation. Next, 
protein bound regions on RNAs is sequenced using HITS technique. Therefore, the 
regulatory sequences including ESE, ESS, ISE, and ISS are identified in the whole 
transcriptome–wide by systematic sequence analysis. Those regulatory protein binding 
regions will represent the essential “footprint” to understand dynamic events of the 
alternative splicing regulation. However, there is limitation that has to be overcome the 
76 
 
specificity of antibody for the RNA binding protein. Finally, various newly developed 
techniques will provide global information to investigate the cancer specific alternative 

































Colorectal cancer is the third most common cancer and leading cause of cancer death in 
the United States. Colon cancer progression involves in the accumulation of sequential 
events that either activate oncogenes or inhibit the action of tumor suppressor genes. 
Particularly, Krüppel-like factor 4 (KLF4) is strongly associated with tumorigenesis and 
regulation of proliferation of GI tract epithelium (Wei et al 2006). In this dissertation 
research, we found novel KLF4 splicing variants produced by exon skipping in human 
cancer cell lines as well as colon tumor tissues (Figure 3-1 and Figure 3-2).  
Most human genes including KLF4 produce different mRNAs by alternative splicing 
mechanism and many abnormal splicing processes are associated with human diseases, 
including cancer. However, the molecular relationship between alternative splicing and 
tumorigenesis is not well understood. Therefore, we hypothesized that alternative splicing 
of KLF4 is involved in colorectal cancer. To investigate mechanism of the KLF4 
alternative splicing, we developed KLF4 minigene system (Figure 3-8). Mutation study 
of 3’ splice sites on intron-2 showed that mutation of this site suppresses the KLF4 exon 
skipping (Figure 3-8). Moreover, sequence analysis revealed that the unique double 3’ 
splice site contributes to in-frame alternative splice between KLF4L and KLF4S (Figure 
3-9).  
To identify trans-acting factor for KLF4 splicing, we performed gain and loss of 
functional studies with RBM5; RBM5 alters KLF4 splicing ratio (Figure 3-10). In 
addition, several anti-tumorigenic compounds were tested for KLF4 splicing (Figure3-11). 
Interestingly, sulindac sulfide restored KLF4L expression and this is mediated by 
dephosphorylation of RBM5 (Figure 3-12).  
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Furthermore, KLF4S localizes in the cytoplasm and nucleus and antagonizes KLF4L 
biological functions including the promoter binding activity to KLF4 target gene and 
binding with β-catenin (Figure 3-14, 15, 16, and 17).  
Our data suggest that RBM5 plays a critical role in alternative splicing of KLF4 and 
KLF4S may contribute to colorectal tumorigenesis by competing with KLF4L. In 
conclusion, we propose a model of the KLF4 alternative splicing mechanism (Figure 3-
18). Finally, KLF4S can be used as a potential diagnostic and prognostic marker for 
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